Key result
The protective axis of the renin-angiotensin system and centrally acting RAS-targeting drugs may offer beneficial effects in brain disorders beyond blood pressure regulation.
Why the study?
Do drugs targeting the central protective axis of the renin-angiotensin system improve outcomes in brain disorders?
Do drugs targeting the central protective axis of the renin-angiotensin system improve outcomes in brain disorders?
Targeting the depressor/protective axis of the renin-angiotensin system may offer novel therapeutic strategies for neurological and cognitive disorders beyond traditional blood pressure control.
Answers are grounded in this paper and cite their sources.
Brain RAS axes may shape central BP control; leaves open targeted interventions pending clinical data.
All the components of the classic renin-angiotensin system (RAS) have been identified in the brain. Today, the RAS is considered to be composed mainly of two axes: the pressor axis, represented by angiotensin (Ang) II/angiotensin-converting enzyme/AT1 receptors, and the depressor and protective one, represented by Ang-(1-7)/ angiotensin-converting enzyme 2/Mas receptors. Although the RAS exerts a pivotal role on electrolyte homeostasis and blood pressure regulation, their components are also implicated in higher brain functions, including cognition, memory, anxiety and depression, and several neurological disorders. Overactivity of the pressor axis of the RAS has been implicated in stroke and several brain disorders, such as cognitive impairment, dementia, and Alzheimer or Parkinson's disease. The present review is focused on the role of the protective axis of the RAS in brain disorders beyond its effects on blood pressure regulation. Furthermore, the use of drugs targeting centrally RAS and its beneficial effects on brain disorders are also discussed.
No takes yet. Share an insight, caveat, or question.
Gironacci et al. (2018) conducted a review in Brain disorders. Drugs targeting centrally RAS was evaluated. The protective axis of the renin-angiotensin system and centrally acting RAS-targeting drugs may offer beneficial effects in brain disorders beyond blood pressure regulation.
Synapse has enriched 10 related papers. Consider them for comparative context: